The role of relative hyperprolactinemia in the genesis of the оvarian follicular cysts development




follicular ovarian cysts, hyperprolactinemia, stress, Сyclodinone®.


Follicular ovarian cysts (FOC) today occur in 25–30% in the structure of all tumors and tumor-like formations in gynecological practice and tend to increase. The study presents the results of using four different treatment regimens for FOC treatment in patients aged 18 to 42 years. Group I (n = 46) consisted of women with uncomplicated course of FOC who received complex hormonal therapy for 3 months. Group II (n = 49) patients who received monotherapy with a special extract of the Vitex Agnus Castus BNO 1095 (Cyclodynon®) for 6 months. Group III (n = 47) – patients who received a combination of hormone therapy (3 months) and BNO 1095 (6 months). Group IV (n = 35) – patients who did not receive drug therapy (expectant tactics + lifestyle modification).

The highest efficacy in relation to the elimination of FOC and the stability of the result during the year was observed in patients of group III who received complex hormone therapy + BNO 1095 extract. Elimination of FOC in 100% of patients within 3 months with a result of more than 95% of patients during the year. Complex hormonal therapy without the use of BNO 1095 (group I) also showed a rather high efficiency with respect to the regression of FOC, but the result was not stable. During the year, relapses in the formation of FOC were observed in 37% of patients. Monotherapy BNO 1095 (group II) demonstrated the efficacy of resorption of the cyst for 6 months in 87% of cases, with the result being preserved for over a year in almost 80% of patients. Active observation (group IV) showed fairly low efficacy: after a year of observation FOC had more of 63% of patients.

The average prolactin level in the study groups was higher than the reference values. During the observation period, prolactin levels in all groups except the control group decreased statistically. After 12 months of follow-up, in the group of women who received a combination of hormone therapy with Cyclodynon®, steady normalization of steroid hormones, estradiol and progesterone, was observed, which is explained by the restoration of the biphasic menstrual cycle in most women of this group.

The study confirms the role of functional hyperprolactinemia in the development of FOC and the advisability of prescribing Cyclodynon® in their treatment regimen both in combination with hormone therapy and monotherapy (if there are have contraindications to hormone therapy or reproductive plans).

Author Biographies

Т. Ф Татарчук, SI “O.M. Lukyanova IPOG of the NAMS of Ukraine” State Scientific Institution “CIMT of the NAS of Ukraine”, Kyiv

MD, professor, corresponding member of the NAMS of Ukraine, deputy director for research work, head of the Endocrine Gynecology Department

Head of the the Department of Reproductive Health

Н. В. Косей, State Institution “O.M. Lukyanova IPOG of the NAMS of Ukraine”, leading researcher, Department of Reproductive Health of State Scientific Institution “CIMT of the NAS of Ukraine", Kyiv

MD, professor, chief researcher, Endocrine Gynecology Department

О. В. Занько, State Scientific Institution “CIMT of the NAS of Ukraine”, Kyiv

PhD, researcher, Department of Reproductive Health

О. Г. Околох, Ivano-Frankivsk Medical Academy, Ivano-Frankivsk

Graduate student

Department of Obstetrics and Gynecology of postgraduate education


  1. Akter, N., et al “Hyperprolactinemia: A Systematic Review of Diagnosis and Management.” Delta Medical College Journal 6.2 (2018): 90–101.
  2. Baerwald, A.R., et al. “Effects of oral contraceptives administered at defined stages of ovarian follicular development.” Fertility and sterility 86.1 (2006): 27–35.
  3. Dekkers, O.M., et al. “Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis.” The Journal of Clinical Endocrinology & Metabolism 95.1 (2010): 43–51.
  4. Kostrzewa, M., et al. “Retrospective analysis of transvaginal ultrasound-guided aspiration of simple ovarian cysts.” Advances in Clinical and Experimental Medicine 28.11 (2019): 1531–5.
  5. La Torre, D., Falorni, A. “Pharmacological causes of hyperprolactinemia.” Therapeutics and Clinical Risk Management 3.5 (2007): 929–51.
  6. Molitch, M.E. “Pathologic hyperprolactinemia.” Endocrinology and metabolism clinics of North America 21.4 (1992): 877–901.
  7. Mong-Ting, L., Bruot, B.C., Adams, W.C. “Hormonal changes during the early development of ovarian cysts in the rat.” Biology of reproduction 35.3 (1986): 542–8.
  8. MacKenna, A., et al. “Clinical management of functional ovarian cysts: a prospective and randomized study.” Human reproduction 15.12 (2000): 2567–9.
  9. Miyamoto, B.E., Galecki, M., Francois, D. “Guidelines for antipsychotic-induced hyperprolactinemia.” Psychiatric Annals 45.5 (2015): 266–72.
  10. Molitch, M.E. “Pathologic hyperprolactinemia.” Endocrinol Metab Clin North Am 21.4 (1992): 877–901.
  11. Gevorkyan, M.A. “Prevention of the formation of functional cysts.” Effective pharmacotherapy 5 (2015): 50–55.
  12. Wang, A.T., et al. “Treatment of hyperprolactinemia: a systematic review and meta-analysis.” Systematic reviews 1.1 (2012): 33.
  13. Tatarchuk, T.F., Kosei, N.V., Tutchenko, T.N. “Treatment of stress-induced luteal phase insufficiency.” Women's Health 3 (2016): 18–23.
  14. “Hyperprolactinemia in the genesis of stress-induced infertility. The possibilities of fitotherapy.” Women's Health 3 (2017): 28–36.



How to Cite

Татарчук, Т. Ф., Косей, Н. В., Занько, О. В., & Околох, О. Г. (2020). The role of relative hyperprolactinemia in the genesis of the оvarian follicular cysts development. REPRODUCTIVE ENDOCRINOLOGY, (53), 23–29.